Beta2-adrenergic System and Training

Healthy Clinical Trial

Official title:

Trainability of the beta2-adrenergic System With Respect to Performance

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT04616261
• Other study ID #: FOREX
• Status: Not yet recruiting
• Phase: N/A
• Start date: November 10, 2020
• Est. completion date: November 10, 2022

Study information

• Verified date: November 2020
• Source: University of Copenhagen
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This project aims to examine the trainability of the beta2-adrenergic system with respect to the individual performance response

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 30
• Est. completion date: November 10, 2022
• Est. primary completion date: November 10, 2022
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Male
• Age group: 18 Years to 45 Years

Eligibility

Inclusion Criteria:

• 18 to 45 years of age

• Trained individuals with a maximal oxygen uptake above 55 ml/min/kg

• Body mass index lower than 26

Exclusion Criteria:

• Allergy towards study drug

• Unacceptable side effects to the study drug

• Chronic disease deemed by the MD to interfere with the study

• Smoking

• Use of prescription medicine

Related Conditions & MeSH terms

• Healthy

Intervention

Behavioral:
• Training
6 weeks of training

Drug:
• Formoterol
inhalation of 54 microg formoterol
• Placebo
inhalation of placebo

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
University of Copenhagen

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Sprint performance	Change in power output during maximal cycling in response to formoterol	½ hour after administration of formoterol or placebo
Secondary	Cycling endurance performance	Change in 4-min time trial performance in response to formoterol	½ hour after administration of formoterol or placebo